

From: Wood, Lorraine
Sent: Thursday, January 19, 2017 6:14 PM
To: MaryAnn Lamb <MaryAnn.Lamb@bpl-us.com>
Subject: Information Request for BLA 125644: HAS 5% and 25%
Importance: High

Dear Dr. Lamb,

We are reviewing your submission for BLA 125644/o Human Albumin Solution (HAS) 5% and 25% and we request the following information to continue our review:

1. In section 3.2.S.4.2 Analytical Procedures, 1.2 NAT tests for (b) (4), HBV, HCV HIV-1 and B19, it states the NAT tests were performed by (b) (4) on the (b) (4). In order for us to continue our review please submit detailed description of the method that was utilized for NAT Tests.

Please contact me if you have any questions.

Sincerely,
Lorraine

Lorraine D. Wood, MS, MLS(ASCP)^{CM}
Regulatory Project Manager

Center for Biologics Evaluation and Research
Office of Blood Research and Review
U.S. Food and Drug Administration
Tel: 240-402-8439
lorraine.wood@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.